Abstract: Methods for providing high-speed connectivity to an aircraft in flight from a satellite. Example methods include transmitting first radio frequency signals from a wide-beam antenna at the satellite at a beamwidth of at least 6 degrees orbital arc to provide a wide coverage area. The first radio frequency signals are transmitted at a first frequency of at least 10 gigahertz and at a low equivalent isotropic radiated power. The method also includes receiving second radio frequency signals from a mobile antenna located on the aircraft, wherein the second radio frequency signals are received at a second frequency of at least 13.75 gigahertz, and the second frequency is different than the first frequency.

Abstract: The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.

Abstract: Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.

Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.

Abstract: Fast and simple method of detecting the presence of chloramphenicol, a harmful compound if present in food products. The method makes use of a mutant chloramphenicol acetyltransferase (CAT) and a fluorophore-linked chloramphenicol in a system where chloramphenicol and the fluorophore-linked chloramphenicol competes for the active site of the mutant CAT. Because the fluorophore-linked chloramphenicol reduces its fluorescence upon binding to the active site and vice versa increases its fluorescence upon being displaced from the active site by the presence of unmodified chloramphenicol in a sample, the increase of fluorescence caused by a testing sample indicates the presence of chloramphenicol.

Abstract: Fast and simple method of detecting the presence of chloramphenicol, a harmful compound if present in food products. The method makes use of a mutant chloramphenicol acetyltransferase (CAT) and a fluorophore-linked chloramphenicol in a system where chloramphenicol and the fluorophore-linked chloramphenicol competes for the active site of the mutant CAT. Because the fluorophore-linked chloramphenicol reduces its fluorescence upon binding to the active site and vice versa increases its fluorescence upon being displaced from the active site by the presence of unmodified chloramphenicol in a sample, the increase of fluorescence caused by a testing sample indicates the presence of chloramphenicol.

Abstract: A safer flash-bang grenade that yields the state of the art sound intensity, plus a brighter, more intense flash of the order of 13.5 million candela—which effect is due to a combination of a particularly efficacious pyrotechnic formulation and a particular reaction chamber design that momentarily retains or holds-back the reaction escape until the desired intensity is reached. The particular pyrotechnic formulation is based upon a strontium nitrate oxidizer in conjunction with an aluminum powder metallic fuel and a sulfur non-metallic fuel. The particular reaction chamber design includes a relatively rigid, non-fragmenting charge holder, with a slip-fit thin aluminum sleeve internal thereof and a shrink fit or other sealed sleeve external thereof.

Abstract: There is provided a method for accessing at least one digital file from a collection comprising more than one digital file in an electronic device, including: generating one index comprising of information entries obtained from each of the more than one digital file in the collection, with each digital file in the collection information being linked to at least one information entry; receiving a speaker independent speech input in at least one language during a speech reception mode; determining a language of the speech input; and setting the speech reception mode to the language of the speech input; comparing the speech input received during the speech reception mode with the entries in the index. The file may advantageously be accessed when the speech input coincides with at least one of the information entries in the index. The digital files may be stored in the electronic device, any device functionally connected to the electronic device or a combination of the aforementioned.

Abstract: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.

Abstract: Means are disclosed by which developers of network-analysis applications may develop network-analysis applications that can interface with multiple different versions of network-management applications, wherein each version of network-management application may have a different interface implementation, without having to be familiar with the different interface implementations. In particular embodiments disclosed herein, a network-analysis application requests and receives version information from a version of a network-management application. Based on the received version information, the network-analysis application selects version-dependent interface-implementation software and then integrates the selected version-dependent interface-implementation software with a version-independent interface-façade to produce an interface between the network-analysis application and the version of the network-management application.